TY - JOUR
T1 - Functionalized Biomimetic Magnetic Nanoparticles as Effective Nanocarriers for Targeted Chemotherapy
AU - Peigneux, Ana
AU - OLTOLINA, FRANCESCA
AU - COLANGELO, Donato
AU - Iglesias, Guillermo R.
AU - Delgado, Angel V.
AU - Prat, Maria
AU - Jimenez‐Lopez, Concepcion
N1 - Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019
Y1 - 2019
N2 - Novel MamC-mediated biomimetic magnetic nanoparticles (BMNPs) are proposed as valuable carriers for targeted chemotherapy because of the size (36 ± 12 nm) and of surface properties conferred by MamC coating. They are super-paramagnetic at room and body temperatures, have a large magnetic moment per particle, mediate hyperthermia, are cytocompatible, and, having a negative surface charge at physiological pH, can be efficiently coupled with DOXOrubicin (DOXO) and a monoclonal antibody (mAb) directed against the human Met/hepatocyte growth factor receptor (overexpressed in many cancers) displaying coupling stability, while releasing DOXO at acidic pH. This release can be enhanced by hyperthermia. The DOXO-mAb-BMNPs selectively recognize Met, bind efficiently to Met+ tumor cells, and discharge DOXO within their nuclei more efficiently than DOXO-BMNPs, exerting cytotoxicity. These data represent proof of concept for future in vivo experi-ments in which the controlled dual targeting (mAb-mediated and magnetic) approach and combined (chemotherapy and hyperthermia) therapy will be studied
AB - Novel MamC-mediated biomimetic magnetic nanoparticles (BMNPs) are proposed as valuable carriers for targeted chemotherapy because of the size (36 ± 12 nm) and of surface properties conferred by MamC coating. They are super-paramagnetic at room and body temperatures, have a large magnetic moment per particle, mediate hyperthermia, are cytocompatible, and, having a negative surface charge at physiological pH, can be efficiently coupled with DOXOrubicin (DOXO) and a monoclonal antibody (mAb) directed against the human Met/hepatocyte growth factor receptor (overexpressed in many cancers) displaying coupling stability, while releasing DOXO at acidic pH. This release can be enhanced by hyperthermia. The DOXO-mAb-BMNPs selectively recognize Met, bind efficiently to Met+ tumor cells, and discharge DOXO within their nuclei more efficiently than DOXO-BMNPs, exerting cytotoxicity. These data represent proof of concept for future in vivo experi-ments in which the controlled dual targeting (mAb-mediated and magnetic) approach and combined (chemotherapy and hyperthermia) therapy will be studied
UR - https://iris.uniupo.it/handle/11579/103344
U2 - 10.1002/ppsc.201900057
DO - 10.1002/ppsc.201900057
M3 - Article
SN - 0934-0866
JO - Particle and Particle Systems Characterization
JF - Particle and Particle Systems Characterization
ER -
